Cabozantinib - Exelixis/Ipsen

Drug Profile

Cabozantinib - Exelixis/Ipsen

Alternative Names: BMS-907351; Cabometyx; Cabozantinib s-malate; Cometriq; XL-184

Latest Information Update: 18 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Duke University Medical Center; Exelixis; Ipsen; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Roche; Swedish Orphan Biovitrum; Takeda
  • Class Amides; Anilides; Antineoplastics; Cyclopropanes; Fluorine compounds; Quinolines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Hepatocellular carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Thyroid cancer
  • Phase III Hepatocellular carcinoma
  • Phase II Bone metastases; Brain metastases; Breast cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Merkel cell carcinoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Urogenital cancer
  • Phase I/II Multiple myeloma; Solid tumours
  • No development reported Acute myeloid leukaemia; Astrocytoma; Cancer; Colorectal cancer; Glioblastoma
  • Discontinued Prostate cancer

Most Recent Events

  • 30 Nov 2017 Dana-Farber Cancer Institute, Exelixis and Bristol-Myers Squibb initiates enrolment in a phase II trial for Breast cancer (Combination therapy, Metastatic disease) in USA (PO) (NCT03316586)
  • 24 Nov 2017 Cabozantinib is still in Phase I development for Solid tumours in Japan (3285061; Takeda Q2 report 2017)
  • 21 Nov 2017 Phase-I/II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in USA (PO) (NCT03170960)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top